PREVACID
LANSOPRAZOLE
Approval overview PREVACID is listed in Drugs@FDA under application 020406 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2023-08-08 00:00:00.
Structured Monograph
Clinical summary
Approval overview PREVACID is listed in Drugs@FDA under application 020406 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2023-08-08 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.